(MENAFNEditorial)
Taiwan is one of the most attractive and stable prospects in the region for pharmaceutical and healthcare investment but i s not without flaws. Weaknesses in the country's regulatory regime and drug pricing concerns will continue to deter multinational interest over our forecast period. While our forecasts going into 2015 are unchanged from the previous quarter BMI believes that Taiwan's export market is poised to benefit greatly from its advantageous position in API manufacturing and the high regard for Taiwanese private healthcare services in the region.
Headline Expenditure Projections
* Pharmaceuticals: TWD160.66bn (USD5.41bn) in 2013 to TWD167.74bn (USD5.59bn) in 2014; +4.4% in local currency terms and +3.4% in US dollar terms. Forecast unchanged from previous quarter .
* Healthcare: TWD964.25bn (USD32.47bn) in 2013 to TWD1004.83bn (USD33.49bn) in 2014; +4.2% in local currency terms and +3.2% in US dollar terms. Forecast unchanged from the previous quarter's projections.
Full Report Details at
- http://www.fastmr.com/prod/924306_taiwan_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=101
Risk/Reward Index
Taiwan has moved down one place in our index from fourth to fifth out of the 19 key markets. We have given the country a score of 64.5 for Q115 down slightly from 65.7 in Q414 resulting in it now coming behind Hong Kong in our regional matrix. While it is a small pharmaceutical market Taiwan boasts above-average Rewards and Risks propped up by factors such as high per capita consumption of medicines and an excellent chance to capitalise on the mainland-China market. Taiwan has a very strong active pharmaceutical ingredient (API) industry. Although it is small which makes the domestic market competitive and particularly constraining it excels at providing specialty chemicals and high-quality APIs for global needs. The now-annual price adjustments will certainly fuel the need for local companies to outgrow the small domestic market.
Key Trends & Developments
November
The Taiwan Health Reform Foundation (THRF) has claimed that the National...
The Taiwan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Taiwan Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Taiwanese pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Taiwan to test other views - a key input for successful budgeting and strategic business planning in the Taiwanese pharmaceutical and healthcare market.
* Target business opportunities and risks in the Taiwanese pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Taiwan.
* Assess the activities strategy and market position of your competitors partners and clients via our Company Profiles (inc. SWOTs KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis and taken together with BMI's political economic and business environment SWOTS it gives a complete overview of market climate.
Market Summary
Snapshot of key market characteristics including total size of pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape.
Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as an analysis of the overall regulatory burden.
Industry Developments
Focus on government healthcare reforms epidemiological trends company M&As product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions plus analysis of key downside risks to the main forecast including:
Healthcare: Total healthcare expenditure (US$bn) healthcare expenditure (% of GDP) healthcare expenditure per capita (US$) hospital beds (per `000 population) doctors (per `000 population) birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn) drug expenditure (% of GDP) drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn) prescription sales (% of total sales) sales broken down by 14 therapeutic areas (cardiovascular anti-infectives etc.)
Generic drug market: Generic product sales (US$bn) generic sales (% of total sales)
OTC drug market: OTC sales (US$bn) OTC sales (% of total sales) sales broken down by product types (analgesics skin treatments vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn) medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against US$ government expenditure external debt.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.